Rebif^® showed an early onset of treatment effect on new or enlarging lesions vs placebo⁶ As early as month 4, 69% reduction in CUA lesions with Rebif^® vs placebo (P<0.01).⁶
CUA = combined unique active (new Gd+ lesions); * Primary endpoint; RR: Relative reduction; AR: Absolute reduction

Rebif^® reduced MRI activity in CIS patients vs placebo ba >80%.¹¹ Significant difference between treatment groups for mean number of CUA lesions per patient per scan (qw vs placebo, P<0.001; tiw vs placebo, P<0.001).^11†‡
CIS=Clinically isolated syndrome; † 2-sided stratified non-parametric ANOVA model on ranked data with effects for treatment group and randomisation stratification factors; ‡ Negative binomial model with treatment and randomisation stratification factors as covariates and log number of scans as offset variable; § The licensed posology of Rebif^® is 44 μg 3 times a week subcutaneously; ** Negative binomial model with treatment and randomisation stratification factors as covariates and log number if scans as offset variable; CUA = combined unique active (new or persisting gadolinium-enhancing lesion on T1 MRI or a new or enlarging lesion on T2 MRI)

Rebif^® reduced the number of CUA lesions over time vs IFN β-1a IM.⁵ Maximum effect observed within 2 to 3 months of starting treatment through month 6.⁵
CUA = combined unique active (defined as an active lesion on T1 post-Gd or T2 sequences, or both, avoiding double counting)